Health & Biotech
PharmAust (ASX: PAA) has changed its name to Neurizon Therapeutics - NUZ (ASX: NUZ).
Below are the previous articles from PharmAust (ASX: PAA):
RELATED STOCKHEAD STORIES
News
Closing Bell: ASX up but MinRes slumps on lithium downgrade; China stocks also sink
Stockhead TV
Long Shortz with PharmAust: Sweet incentives for sad disease’s drug development
Health & Biotech
Health Kick Podcast: PharmAust in the fight against MND and ALS with lead drug monepantel
The Ethical Investor: Falling birth rates propel pets sector, and why ESG investors should tap into it
Health & Biotech
ASX stocks leading clinical trials in Australia
News
Closing Bell: ASX choppy as traders sit it out; BPM soars on Mt Gibson gold find
Health & Biotech
PharmAust seeks orphan drug designation in Europe for monepantel to treat ALS
Health & Biotech
Morgans sees big upside for PharmAust if monepantel succeeds
Health & Biotech
PharmAust reports positive interim results of OLE study on monepantel to treat ALS
Health & Biotech
ASX Health Stocks: Actinogen skyrockets 125pc on antidepressant drug trial results
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
Health & Biotech
ScoPo’s Powerplays: ASX health stocks up in ‘fairly lacklustre week’
News
ASX Small Caps Lunch Wrap: The ASX is all red after a night to forget for US tech
Health & Biotech
PharmAust raises $7.8 million in hot SPP
Health & Biotech
PharmAust’s monepantel drug hits strategic milestone with selection for prestigious ALS treatment trial
Health & Biotech
ScoPo’s Powerplays: ASX health stocks hit resistance in first week of FY25
Stockhead TV
